Artiva Biotherapeutics (ARTV) Revenue (2023 - 2024)

Artiva Biotherapeutics' (ARTV) quarterly Revenue came in at $251000.0 in Q1 2024, down 89.32% on a QoQ basis from $2.4 million in Q4 2023.

Artiva Biotherapeutics (ARTV) Revenue (2023 - 2024) Analysis & Trends

Artiva Biotherapeutics (ARTV) has 2 years of Revenue data on file, last reported at $251000.0 in Q1 2024.

On a quarterly basis, Revenue changed N/A year-over-year to $251000.0 in Q1 2024; TTM through Dec 2024 was $251000.0, a N/A change from a year earlier, with the FY2024 full-year figure at $251000.0, down 99.25% from the prior year.
Revenue for Q1 2024 stood at $251000.0, down from $2.4 million in the prior quarter.
Over the last five years, Revenue for ARTV reached as high as $26.7 million in Q3 2023 and fell as low as $251000.0 in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	1.51 Bn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	2.99 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	3.61 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	1.56 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Artiva Biotherapeutics	249.99 Mn	249.99 Mn	-	-

Download Data